#EULAR2020 #op0148 real world European study of Mepolizumab in 142 pts w/EGPA shows significant improvement of general, ENT, pulm&neuro symptoms. Significant reduction in BVAS, 90%decrease of asthma attacks by 12 mo, decreased steroid use. 21.1%non-serious AEs @RheumNow https://t.co/fN4tKPvUaE